Immunotherapy developments in lung, head and neck, liver and PD-1 repsonse prediction

Bookmark and Share
Published: 29 May 2015
Views: 2430
Dr Lynn Schuchter - University of Pennsylvania, Philadelphia, USA

Dr Schuchter gives an expert commentary at ASCO 2015 on immunotherapy data presented on the first day:

- A 132-patient study indicating that pembrolizumab immunotherapy is effective for patients with recurrent or metastatic head and neck cancer (HNC)

- Genomic marker predicts anti-PD-1 response in several cancers

- Findings from a phase I/II study that suggest that nivolumab is safe and effective in advanced liver cancer

- Randomised phase III study indicates PD-1 immunotherapy is an effective treatment option for NSCLC

Read the news article or watch the press conference for more.